Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cytokinetics plunges as tirasemtiv fails to BENEFIT-ALS

This article was originally published in Scrip

Executive Summary

Cytokinetics lost $303m worth of market value on 25 April after the company reported that its drug tirasemtiv caused a greater numerical loss of function for individuals with amyotrophic lateral sclerosis (ALS) than placebo in the 711-patient Phase IIb BENEFIT-ALS clinical trial.

You may also be interested in...



Seven Clinical Trial Read-Outs Due In Q4

The last three months of the year should see data reporting from a number of key studies for novel products including Roche's emicizumab. Scrip takes a look at some of the more interesting studies expected by year end, with the help of analysts from Informa's Biomedtracker.

Cytokinetics Seeks ALS Success By Focusing On Lung Function

Despite an earlier Phase II failure on broader ALS endpoint, biotech thinks it can demonstrate efficacy in slowing lung-function decline in ALS patients.

Astellas Targets ALS In Expansion Of Cytokinetics Alliance

Astellas and Cytokinetics are expanding their existing alliance to investigate two candidates against amyotrophic lateral sclerosis, as the Japanese firm looks to build its strategic interests in muscle disease.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC025135

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel